Table 3.

Effect of L-NAME and indomethacin on relaxing effects of PHAR-DBH-Me on aortic rings with and without endothelium pre-contracted with PHEN

Condition	Groups
	PHAR-DBH-Me	PHAR-DBH-Me + Indo	PHAR-DBH-Me + L-NAME	PHAR-DBH-Me + Indo + L-NAME
With endothelium
pD2	6.01 ± 0.46	9.48 ± 0.54*	6.13 ± 0.92*	10.06 ± 0.36*
% Max. Tension	66.80 ± 8.12	44.76 ± 8.75*	91.35 ± 10.75*	62.35 ± 5.34
Without endothelium
pD2	Infinite	Infinite	7.64 ± 0.57*	7.92 ± 0.39
% Max. Tension	105.33 ± 9.27	99.74 ± 12.07	92.99 ± 5.27	83.93 ± 10.55

Data are presented as the average ± SD. pD₂: –Log of the average of the molar concentration that produced 50% of the maximum relaxation induced by PHAR-DBH-Me (10^–12–10^–5 M). Max Tension corresponds to the average percentage of the tension decrease compared to the maximum tension developed in response to phenylephrine (PHEN) (10^–6 M). PHAR-DBH-Me: control group; PHAR-DBH-Me + Indo: PHAR-DBH-Me in presence of indomethacin (10^–6 M); PHAR-DBH-Me + L-NAME: PHAR-DBH-Me in presence of L-NAME (300 µM); PHAR-DBH-Me + Indo + L-NAME: PHAR-DBH-Me in presence of indomethacin (10^–6 M) plus L-NAME (300 µM). *Denotes that the differences are significant respect to the control group (p < 0.05). n = 5 rats in each group.